Taoiseach Micheál Martin visits APC to review research and development of Covid-19 vaccine in Ireland
APC’S research work aims to reduce the time for patient access to a coronavirus vaccine (COVID-19)
Dublin, Ireland – 4 September 2020: APC, the award-winning Irish pharmaceutical research and development company, today welcomed An Taoiseach Micheál Martin to its headquarters in Dublin. During the visit, An Taoiseach reviewed APC’s plans to expedite the development and manufacture of a coronavirus vaccine (COVID-19) in Ireland, in partnership with Australian biotechnology firm Vaxine Pty.
APC partners with the global pharmaceutical and biotech industry to accelerate the development and launch of high-quality, life-changing medicines and vaccines. APC currently employs a team of 130 people and is the one of the largest Irish employers of PhD-qualified scientists and chemical engineers.
Established in 2011 by Dr Mark Barrett (CEO) and Professor Brian Glennon (CTO), APC utilises its platform technology, BioACHIEVE®, and globally recognised research team to accelerate how drug and vaccine manufacturing processes are researched and developed. In addition to the Covid-19 vaccine candidate, APC is currently working on 20+ medicines for a variety of cancers, respiratory diseases, Alzheimer’s disease and HIV at its 60,000 sq. ft. HQ in Dublin.
Commenting on this visit from An Taoiseach, APC Chief Executive Officer Dr. Mark Barrett said: “As an Irish pharmaceutical research and development company we are proud to be at the forefront of the science and engineering required to bring a Covid-19 vaccine from an idea to reality. From an Ireland Inc perspective, it is vital that a research-to-manufacturing solution here in Ireland is realised. We are pleased to be working with our global partner Vaxine, Enterprise Ireland and the Irish Government to establish this solution and to accelerate the journey for Covid-19 vaccines and treatments in Ireland.”
Commenting on this visit, An Taoiseach Micheál Martin said: “I would like to thank the management and team at APC for inviting me to their facility to see the complex and challenging work being undertaken by their staff as they continue in their efforts to develop a vaccine and treatment for Covid-19. From a national perspective, it is particularly impressive to witness an Irish company so involved in the search for a Covid-19 vaccine.”
Enterprise Ireland CEO Julie Sinnamon, who was also in attendance for the Covid-19 vaccine review, commented: “As an indigenous Irish company, APC is pushing the boundaries and innovating so that a Covid-19 vaccine can be accelerated to market. Enterprise Ireland has a long history of working with APC and are proud to stand with them as they define a path forward for pharmaceutical research in Ireland.”
Through the development of innovative synthetic and biological processes, APC accelerates the delivery of high-quality, life-changing medicines to patients. These processes help reduce development time frames along with the costs and risk associated with the development of new medicines. Partnering with eight of the top 10 pharmaceutical companies and five of the top 10 biotech companies worldwide, APC works across a wide range of therapeutic areas.
For further details, please contact:
Breda Brown / David Clancy
Tel: (01) 5225200 / 087 248 2495 (DC)